Development of Vaccine for Preventing HTLV-I and HIV Infection and Disease Development Using Vaccinie Virus Vector
Development of Vaccine for Preventing HTLV-I and HIV Infection and Disease Development Using Vaccinie Virus Vector
批准号:
01870022
负责人:
SHIDA Hisatoshi
金额:
$20.61万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research
财政年份:
1989
资助国家:
日本
项目状态:
已结题
起止时间:
1989 至 1991
中文摘要
(1)我们检测了健康携带者和ATL或HAM患者的CTL活性是否存在差异。研究发现,HAM患者有抗Tax蛋白的CTL,而健康携带者没有。利用人工合成的多肽进行表位定位,揭示了TAX氨基末端的抗原性。这些CTL受HLAA2的限制。测量。T细胞的启动试验显示,在健康携带者中,一些人的T细胞对Px蛋白(Tax、Rex和p2l^X)具有启动作用,而另一人则没有。这些高应答率与HAM患者特有的HLA型有关。免疫后的T细胞有CD8抗原。为鉴定HTLV-I的中和表位,制备了具有中和活性的抗env单抗。利用合成肽进行表位定位,发现gp46氨基酸序列191-196是单抗的结合部位。用该多肽免疫兔可产生中和抗体,预防HTLV-I感染。(3)为了构建更高效的RW载体,我们在p7.5启动子区域引入突变,并将其置于重复位置。此外,我们还将它们与ATI启动子结合,产生更强的启动子。以CAT基因作为报告基因的表达效果,合成的CAT蛋白约占细胞总蛋白的5%。(4)构建了ATI杂合启动子控制下携带SIV env基因的RW。用该RVV免疫食蟹猴后,用SIV攻击,检测其预防感染的能力。所有三只被挑战的猴子都感染了SIV。实验二,在RW免疫后注射部分纯化的env蛋白作为佐剂,然后用SIV攻击猴。免疫的三只猴子中有一只受到保护。
英文摘要
(1) We examined whether there is deference between CTL activities of healthy carriers and that of ATL or HAM patients. It has been found that the HAM patients had CTL against Tax protein whereas the healthy carriers did not. Epitope mapping using synthesized peptides revealed the antigenicity of amino terminal of Tax. These CTLs were restricted by HLAA2. Measurement of. priming of T cells revealed that among healthy carriers some had primed T cel-is to pX proteins (Tax, Rex, and p2l^X) and the other did not. These high responses correlated to the HLA types characteristic to HAM patients. The primed T cells had CD8 antigen. These results suggest the relationship between anti Tax CTL and HAM.(2) To identify the neutralization epitope of HTLV-I, anti env MAbs which had the neutralizing activity were produced. Epitope mapping using synthetic peptides revealed the gp46 amino acid sequence 191-196 as the binding site of the MAb. Immunization of the rabbits by this peptide elicited neutralizing antibody and prevented HTLV-I infection.(3) To construct more efficient RW vectors, we introduced mutations into the region of p7.5 promoter and then placed them in tandemly repeated position. Furthermore we combined them with ATI promoter to produce stronger promoter. When we measure its efficacy by expression of CAT gene as a reporter, CAT protein was synthesized whose amount was approximately 5% of that of total cell proteins.(4) We constructed the RW which harbors the SIV env gene under the control of ATI hybrid promoter. After cynomologous monkeys were immunized with this RVV, they were challenged by SIV to examine its capability of preventing infection. All three monkeys challenged were infected by SIV. In the second experiment, partially-purified env protein was injected as booster after the immunization by the RW, and then the monkeys were challenged by SIV. One of three monkeys immunized was protected.
期刊论文(57)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
M.Kannagi.,H.Shida.,et al.: "Human Tーcell leukemia virus type I (HTLVーI)ーspecific cytotoxic T cells from a patient with HTLVーI associated myeolopathy preferentially recognize cells expressing HTLVーI pX vitro."
M. Kannagi.、H. Shida. 等人:“来自 HTLV-I 相关骨髓病患者的人类 T 细胞白血病病毒 I 型 (HTLV-I) 特异性细胞毒性 T 细胞优先识别表达 HTLV-I pX 的细胞体外。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
N.Yoshimura.: "Simian T-cell leukemia virus type-I specific killer T-cells in naturally infected African green monkey carriers." J.Immunol.144. 2173-2178 (1990)
N.Yoshimura.:“自然感染的非洲绿猴携带者中的猿 T 细胞白血病病毒 I 型特异性杀伤 T 细胞。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
N. Yoshimura.: "Simian T-cell leukemia virus type-I specific Killer T-cells in naturally infected African green monkey carriers." J. Immunol.144. 2173-2178 (1990)
N. Yoshimura.:“自然感染的非洲绿猴携带者中存在猿 T 细胞白血病病毒 I 型特异性杀伤 T 细胞。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y.Noguchi et al.: "Rat cytotoxic T lymphocytes against T lymphotropic virus type I-infected cell recognize gag and env gene encoded antigens." J.Immunol.143. 3737-3742 (1989)
Y.Noguchi 等人:“针对 I 型嗜 T 淋巴细胞病毒感染细胞的大鼠细胞毒性 T 淋巴细胞识别 gag 和 env 基因编码的抗原。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M. Kannagi.: "Predominant recognition of human T cell leukemia virus type I (HIVL-I) pX gene products by human CD8^+ cytotoxic T cells directed against HTLV-I-infected cells." Inter. Immunol.3. 761-767 (1991)
M. Kannagi.:“针对 HTLV-I 感染细胞的人类 CD8+ 细胞毒性 T 细胞对人类 T 细胞白血病病毒 I 型 (HIVL-I) pX 基因产物的主要识别。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 26 条
Specific recovery of exhausted T cells against HTLV-1
-
批准号:23650606
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:SHIDA Hisatoshi
-
依托单位:
Elicitation of broad neutralizing antibodies to HIV-1 and development of infection rat model
-
批准号:21390135
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.15万
-
财政年份:2009
-
负责人:SHIDA Hisatoshi
-
依托单位:
Construction of a transgenic rat model, which is highly sensitive to HTLV-1 infection
-
批准号:14370098
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.58万
-
财政年份:2002
-
负责人:SHIDA Hisatoshi
-
依托单位:
Cellular cofactors involved in transport of mRNAs of complex retroviruses and hepatitis B virus
-
批准号:11470079
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$3.07万
-
财政年份:1999
-
负责人:SHIDA Hisatoshi
-
依托单位:
Factor (s) involved in transport of HBV mRNAs
-
批准号:09670315
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.73万
-
财政年份:1997
-
负责人:SHIDA Hisatoshi
-
依托单位:
Development of Recombinant Vaccinia Virus Vaccine Against Adult T-cell Leukemia
-
批准号:62870021
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$12.16万
-
财政年份:1987
-
负责人:SHIDA Hisatoshi
-
依托单位:
Research for developinga multivalent vaccine based onvaccinia virus.
-
批准号:60870019
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$5.89万
-
财政年份:1985
-
负责人:SHIDA Hisatoshi
-
依托单位:
海外基金